GMP cell and gene therapy manufacturing in the UK: facilities, capabilities and capacity

The Cell and Gene Therapy Catapult review of MHRA licensed GMP manufacturing facilities in the UK provides an insightful picture of the capability and capacity of cell and gene therapy manufacturing facilities that are open for collaboration.

Initially a one-off review in 2013, this review is now an important annual undertaking as a result of the recommendation by the House of Lords 2013-14 inquiry into Regenerative Medicine.

Follow the link below to read the full blog published by Phacilitate.

  • FDA approves , a one-time AAV gene therapy indicated for the treatment of patients with a rare form of inh… https://t.co/vO0CyqhjhP 58 min 48 sec ago

Discover who we are